Charles River Laboratories (CRL) Misses Q3 EPS by 1c; Tightens FY11 EPS Outlook
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $295.19 +1.28%
Financial Fact:
Net sales related to products: 132.87M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Net sales related to products: 132.87M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Charles River Laboratories Int'l (NYSE: CRL) reported Q3 EPS of $0.57, $0.01 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $277.6 million versus the consensus estimate of $280.45 million.
Charles River Laboratories sees FY2011 EPS of $2.40-$2.45, versus prior guidance of $2.38-$2.48 and the consensus of $2.45.
Charles River Laboratories sees FY2011 EPS of $2.40-$2.45, versus prior guidance of $2.38-$2.48 and the consensus of $2.45.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
- Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
